0.9801
0.28%
0.0027
Precedente Chiudi:
$0.9774
Aprire:
$0.96
Volume 24 ore:
15,958
Relative Volume:
0.15
Capitalizzazione di mercato:
$33.87M
Reddito:
-
Utile/perdita netta:
$-77.50M
Rapporto P/E:
-0.2553
EPS:
-3.839
Flusso di cassa netto:
$-8.35M
1 W Prestazione:
+1.04%
1M Prestazione:
-7.54%
6M Prestazione:
-76.21%
1 anno Prestazione:
-76.61%
Ocean Biomedical Inc Stock (OCEA) Company Profile
Nome
Ocean Biomedical Inc
Settore
Industria
Telefono
(646) 908-2658
Indirizzo
515 MADISON AVE SUITE 8078, NEW YORK
Ocean Biomedical Inc Borsa (OCEA) Ultime notizie
Dr. Chirinjeev Kathuria - Smart Business Dealmakers
Everything you need to know about Zenas BioPharma’s IPO - AlphaStreet
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - ForexTV.com
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent - GlobeNewswire
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - Morningstar
Ocean Biomedical, Inc. Announces Receipt of Notice from - GlobeNewswire
Ocean Biomedical Faces Nasdaq Compliance Challenges - TipRanks
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - StockTitan
Ocean Biomedical (NASDAQ: OCEA) Research Summary - AlphaStreet
Ocean Biomedical Inc. (OCEA) Stock: Navigating a Year of Volatility - The InvestChronicle
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.16% - MSN
Ocean Biomedical secures additional financing, issues equity - Investing.com
Financial Health Check: Examining Ocean Biomedical Inc. (OCEA)'s Key Ratios – DWinneX - The Dwinnex
Ocean Biomedical Inc. (OCEA) is a good investment, but the stock may be overvalued – US Post News - US Post News
Everything you need to know about OS Therapies’ upcoming IPO - AlphaStreet
3-Month SOFR (SQZ24) Quote - The Globe and Mail
Alumis looks to raise $300 million in IPO. Here’s what you need to know - AlphaStreet
Idiopathic Pulmonary Fibrosis Pipeline Analysis 2024: FDA Approval, Clinical Trials, Therapies, MOA, ROA by - EIN News
The Role of Horseshoe Crabs in the Biomedical Industry and Recent Trends Impacting Species Sustainability - Frontiers
Investing in Ocean Biomedical Inc. (OCEA) might be an excellent idea, but the stock is currently overvalued ... - US Post News
Best Penny Stocks for Today (Charts Updated Daily) • Benzinga - Benzinga
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More - Yahoo Lifestyle UK
Biotech Stocks: The Top 5 To Watch As Shares Broadly Struggle - Investor's Business Daily
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Stocks Fall Before CPI Report and FOMC Meeting - The Globe and Mail
Stocks Settle Higher Ahead of the Tue/Wed FOMC Meeting - The Globe and Mail
Ocean Biomedical congratulates joint venture partner Virion TherapeuticsTipRanks.com - TipRanks
Tempus AI gears up for IPO. Here’s everything you need to know - AlphaStreet
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive ... - GlobeNewswire
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - ForexTV.com
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - GlobeNewswire Inc.
Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress - PR Newswire
Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a ... - PR Newswire
Stocks Climb on Positive Corporate News - The Globe and Mail
Ocean Biomedical receives notice of non-compliance from NasdaqTipRanks.com - TipRanks
Ocean Biomedical Faces Nasdaq Non-Compliance Notice and DelaysTipRanks.com - TipRanks
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form ... - GlobeNewswire
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - GlobeNewswire Inc.
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - Yahoo Finance
Stocks Mixed in TodayAfternoon Trade - Nasdaq
Ratio Review: Analyzing Ocean Biomedical Inc. (OCEA)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023 - InvestorPlace
Ocean Biomedical Inc.’s Shares Reel: 189.95% Quarterly Revenue Decline Amid 60.29M Market Cap - The InvestChronicle
Market Insight: Ocean Biomedical Inc. (OCEA)'s Notable Gain, Closing at 1.74 – DWinneX - The Dwinnex
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - Markets Insider
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - BioSpace
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease - ForexTV.com
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential - Daily Guardian Canada
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - GlobeNewswire
Ocean Biomedical Inc Azioni (OCEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):